Reliable and flexible enterprise network services connect 28 locations in Europe and the United States
McLean, Virginia, July 26, 2022 (Globe Newswire) – GTT Communications, Inc.Announced this, it is the leading global provider of managed networks and security services to multinational organizations LFBB, a leading French biopharmaceutical company, deploys GTT Managed SD-WAN, Cloud Connect, dedicated Internet access, broadband and professional services. The solution covers 28 locations across France, Austria, Czech Republic, Belgium and the United States to support the company’s network transformation strategy.
LFB is a leading company in Europe, providing medical products derived from plasma and recombinant proteins globally to healthcare professionals in immunology, hemostasis and critical care. LFB employs more than 2,500 people in France and all over the world. The company’s network transformation, in support of its increasing transition to cloud applications, necessitates a transition from legacy Multi-Protocol Label Switching (MPLS) WAN infrastructure to a more cost-effective and flexible software-defined networking approach.
GTT’s managed SD-WAN solution leverages the global Tier 1 Internet backbone to provide an enhanced Internet experience for LFB. The network is designed to ensure that enterprise traffic stays on GTT’s global IP network for as much of its journey as possible ensuring quality, best performance and control. The solution connects LFB business applications, cloud sites, and hosting to its headquarters, branches, regional offices, blood collection centers, and four production sites. LFB is supported throughout the service lifecycle by GTT Professional Services, which provides improved planning and execution, as well as ongoing technical support and service management. GTT is also an active member of the IT Governance Steering Committee LFB.
Service uptime, end-user performance optimization, and network reliability is critical to LFB, as this ensures quality and end-to-end product traceability are paramount to the safe and continuous manufacture of its products. Multiple connections are provided at each site, which, along with routing of SD-WAN traffic, ensures a highly flexible setup that meets stringent LFB requirements. In addition, the GTT solution allows LFB to quickly and securely introduce new sites into its network, as well as rapidly increase network capacity at any given site.
“The global pandemic has brought about many changes in how we connect our employees and sites, which highlights the importance of the GTT Network solution in ensuring the continuity of production of our medical products to treat often serious and rare diseases,” said Guillaume Castell, CIO at LFB. “As we look to triple our production capacity over the coming years with the launch of our new production site planned, as well as opening new blood collection centers in several markets, we know we can count on GTT as a trusted partner to help us build on our approach to network and security from for the future of our industry.”
Tom Homer, Head of Europe, GTT said, “We are proud to partner with LFB to support its critical role as a provider of biopharmaceutical products. Managed SD-WAN, Internet capabilities and enhanced services not only increase network reliability and resilience, but also enable LFB to focus its resources on advancing medical testing and life-saving treatments.”
LFB has been a GTT Connect customer since 2017.
GTT is a managed network and security services provider for global enterprises. We design and deliver solutions that leverage advanced cloud, networking, and security technologies. We complement our solutions with a range of professional services and exceptional support teams in local markets around the world. We serve thousands of national and multinational companies with a portfolio that includes SD-WAN, security, internet, voice, and other connectivity options. Our services are uniquely enabled by the world’s top-rated IP backbone that spans over 260 cities on six continents. The company’s culture is built on a customer-first experience that is underpinned by our commitment to operational excellence and continuous improvement in our business and environmental, social and governance practices. For more information visit www.gtt.net.
LFB is a biopharmaceutical group that develops, manufactures and markets medicinal products derived from plasma and recombinant proteins for the treatment of patients with often serious and rare diseases. Founded in France in 1994, LFB is today a leading European company providing medical products derived from plasma and its derivatives to healthcare professionals. Its mission is to offer patients new treatment options for unmet needs in three main treatment areas: immunology, hemostasis and intensive care. LFB’s current market portfolio includes 15 biomedical products sold in nearly 30 countries
For more information, please visit the website www.groupe-lfb.com.